This interplay suggests that the combined inhibition of PI3K/AKT and NOTCH1 may represent a promising therapeutic strategy for high-risk CLL and RT patients [46,47,48]. This evidence concerns the gene AKT1 and B-cell chronic lymphocytic leukemia.